Related Experiment Videos
Chronic myeloid leukemia as an immunological target
1Department of Haematology, University of Wales College of Medicine, Cardiff, UK.
American Journal of Hematology
|January 1, 1997
Summary
T cells play a crucial role in controlling chronic myeloid leukemia (CML). Research shows bcr-abl junctional peptides can be used for CML immunotherapy, offering new treatment strategies.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Clinical observations suggest T cells are involved in chronic myeloid leukemia (CML) control.
- Laboratory studies confirm the presence of CML-specific T cells in healthy individuals and CML patients.
- Both MHC-unrestricted and MHC-restricted immune mechanisms are implicated in CML pathogenesis.
Purpose of the Study:
- To investigate the role of T cells in chronic myeloid leukemia (CML).
- To explore the potential of bcr-abl fusion protein as a leukemia antigen for immunotherapy.
- To evaluate novel immunotherapy strategies for CML management.
Main Methods:
- Analysis of T cell responses to CML-specific antigens.
- Generation and characterization of leukemia-specific T cell lines.
- Investigation of MHC-restricted and MHC-unrestricted immune effector mechanisms.
Main Results:
- Evidence suggests bcr-abl junctional peptides elicit CD4 and CD8 T cell responses in healthy donors and CML patients.
- Generated T cell lines react with autologous or HLA-matched CML cells.
- bcr-abl fusion protein processing in vivo allows for antigen recognition by T cell receptors.
Conclusions:
- bcr-abl junctional peptides show promise for CML immunotherapy.
- Adoptive immunotherapy, cytokine therapy, and immune gene therapy are potential CML treatment strategies.
- Novel immunotherapies may serve as crucial adjuvant treatments for CML patients.